Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

Hozzl · 2024-10-04T19:42:59Z

Explore the details of House Bill 3884 Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

10/4/2024, 7:42 PM

Summary of Bill HR 3884

Bill 118 hr 3884, also known as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023, aims to address the challenges faced by individuals with sickle cell disease and other heritable blood disorders. The bill focuses on research, surveillance, prevention, and treatment of these conditions.

The key provisions of the bill include:

1. Establishing a national surveillance system to track the prevalence and impact of sickle cell disease and other heritable blood disorders. 2. Increasing funding for research into new treatments and potential cures for these conditions. 3. Improving access to quality care for individuals with sickle cell disease and other heritable blood disorders. 4. Enhancing education and awareness efforts to promote early detection and intervention. 5. Supporting programs to improve the quality of life for individuals living with these conditions. Overall, the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 aims to improve outcomes for individuals with sickle cell disease and other heritable blood disorders through a comprehensive approach that includes research, surveillance, prevention, and treatment.

Congressional Summary of HR 3884

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 3884

Bill HR 3884 is currently in the status of Introduced to Senate since September 24, 2024. Bill HR 3884 was introduced during Congress 118 and was introduced to the House on June 7, 2023. Bill HR 3884's most recent activity was Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of September 24, 2024

Bipartisan Support of Bill HR 3884

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 3884

Primary Policy Focus

Health

Potential Impact Areas

- Blood and blood diseases

- Health programs administration and funding

- Health promotion and preventive care

- Hereditary and development disorders

- Medical research

Alternate Title(s) of Bill HR 3884

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.